Abstract
GSK will pay $66 million up front to license a late-stage antibiotic from Spero Therapeutics. The drug, tebipenem pivoxil, is the “first oral carbapenem antibiotic to potentially treat complicated urinary tract infections,” the companies say. In June, the US Food and Drug Administration sent Spero a letter outlining deficiencies in its new drug application for tebipenem. The FDA later informed the firm that it could resubmit the application after completing an additional Phase 3 clinical trial. Spero said it would pursue the trial with a partner firm.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
